Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions
At a glance
Conditions
NCT07654283
Where you'd take part
This study runs at 10 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Clinica Mangiagalli
Milan, Milan, Italyno site contact published
Not yet recruiting
Hôpital Beaujon
Clichy, Franceno site contact published
Not yet recruiting
King's College Hospital
London, London, United Kingdomno site contact published
Not yet recruiting
NYU Langone Health
New York, New Yorkno site contact published
Not yet recruiting
Stanford University
Palo Alto, Californiano site contact published
Not yet recruiting
Texas Liver Institute
San Antonio, Texasno site contact published
Recruiting
Toronto General Hospital
Toronto, Ontario, Canadano site contact published
Not yet recruiting
University of Calgary
Calgary, Alberta, Canadano site contact published
Not yet recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Audrey Lau, MD, PhD · STUDY_DIRECTOR · AusperBio Therapeutics Inc.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Proportion of participants with persistent HBsAg < limit of detection (LOD) and HBV DNA < lower limit of quantification (LLOQ)24 Weeks post AHB-137 treatment (Week 48)